PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Empagliflozin - Diabetes Mellitus

PAD Profile : Empagliflozin - Diabetes Mellitus

Keywords :
SGLT2s, SGLT2 inhibitors, sodium glucose co-transporter 2 inhibitors, diabetic ketoacidosis, DKA
Brand Names Include :
Jardiance

Traffic Light Status

Status 1 of 1.

Status :
Green
Preferred
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
10 February 2025
Surrey Heartlands Medicines Safety Committee (MSC)

The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.

07 February 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
THE PREFERRED SGLT-2 (GLIFLOZIN): In trials empagliflozin has shown to reduce rates of cardiovascular events. Licensed for people up to the age of 84 years. See guidelines below and associated documentation for further information

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More